Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BriaCell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:RE:BCTX To Quickly Regain $8/share

I think you're on the right track here with the 50 and 200DMA.  We now have a situation with both a falling 50 and 200.  This is a red flag for me.  I would have sold back in April...read more

$NIRV looking good

check out the newly listed $NIRV, sheldon also involved with his son, looks like a big winner in the making! https://ceo.ca/@newsfile/nirvana-signs-letter-of-intent-with-innovate-phytotechnologies  rate and reply

RE:BCTX To Quickly Regain $8/share

Well, that did not turn out at all how I imagined it.  I was able to add at these low levels today.  Still think there is really good returns possible here.  I am a holder of company...read more

BCTX To Quickly Regain $8/share

Short-tem, BCTX should quickly regain $8/share to keep the 50-DMA rising and above the 200-DMA.  Very bullish here.  Short-term this will add confidence the recent decline has put in another...read more

RE:BCTX Fast Track FDA Approval

Sell off on great news after a run-up on no news!? What's going on? -TIA  rate and reply

BCTX Fast Track FDA Approval

Well this week's options trading isn't at all suspicious!  I am long so happy about great advancement for company on outstanding news, but someone definitely leaked something for all...read more

Not Puts Being Exercised

Today's action in BCTX is being postulated as PUTS being exercise, but this does not explain the massive purchasing of CALLS all day.  Now it is 12,512 contracts for April 14, 2022 Strike $12...read more

1.1M Options Shares Bought 2 Days Left

Today, BCTX prior to its poster presentation this afternoon has had volatile trading moving around 20% with over 3 million shares traded.  More interesting, there have been 11,000 contracts for...read more

Potential for this company - 10x ($100+/share)

I have bought BCTX aggressively because it is a very undervalued company for it's potential value in its research.  I have been trying to calculate what potential value is if their tech...read more

Massive Short Squeeze Possible Above $10.50

Facts: Currently about 15% of the outstandind shares of BCTX are shorted. Taking into account the tightly held shares by institutions and insider holdings the short position is closer to 40% of float...read more

Likely Trend Up For Break Away Gap

This is just speculation, but the chart action in BCTX is very encouraging going into the AACR on April 12, 2022.  I expect it to continue to rise into the $10-$11 range and build a higher base.&...read more

Keytruda Lung Cancer Reduction, Good News for BCTX Study

Merck just released results for their Keytruda Lung cancer study and it showed a 24% reduction in disease recurrence or death.  Good news for Briacell as this is one of the new therapeutic...read more

No gaps in chart, short interest still high, Lassonde Curve

From a technical perspective it is nice to see BCTX trading in ranges everyday to keep chart tight and clean.  I am not a fan of gap ups as they are filled usually.  A breakaway gap on an...read more

Merck potential bidder for Briacell

Merck as potential bidder for Briacell makes strategic sense: 1)  Merck was already a partner in study with Briacell with their drug Keytruda 2)  Keytruda sales will be $17 billion in 2022...read more

Briacell Presentation Potential Multi-Billion Dollar Value

Dr. William Williams discussing Briacell and what to expect in 2022.  At 13:30 in video he discusses a revaluation and potential for multi-billion dollar valuation. https://www.youtube.com/watch...read more

BriaCell Therapeutics corp HLA scores success

https://scr.zacks.com/news/news-details/2022/BCTX-Game-Set-and-Match-HLAs-Score-Success/default.aspx  rate and reply

Warrants

Given the payoff profiles if you want exposure to BCTX the warrants look extremely cheap vs the stock itself.  rate and reply

29.83

This is how many shares you would get of $APC for every one share of $BCT. One and only post. Just spreading the love. Not a spammer. Just a serially successful VC tossing you guys some early stage...read more

TSXV Acceptance of Normal Course Issuer Bid

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage...read more

Buyback to Purchase up to 10% of Shares & Listed Warrants

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical...read more